BNP Paribas Financial Markets Purchases 21,357 Shares of Twist Bioscience Co. (NASDAQ:TWST)

BNP Paribas Financial Markets grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 128.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,032 shares of the company's stock after purchasing an additional 21,357 shares during the quarter. BNP Paribas Financial Markets owned about 0.06% of Twist Bioscience worth $1,718,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Caprock Group LLC increased its holdings in shares of Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company's stock worth $387,000 after acquiring an additional 220 shares during the last quarter. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. Arizona State Retirement System increased its holdings in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after purchasing an additional 308 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after purchasing an additional 312 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after buying an additional 381 shares during the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 1,057 shares of the company's stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the sale, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This represents a 0.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 in the last ninety days. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Stock Up 3.9 %

Shares of TWST traded up $1.96 during trading hours on Friday, hitting $52.70. 512,209 shares of the company were exchanged, compared to its average volume of 941,345. Twist Bioscience Co. has a fifty-two week low of $24.81 and a fifty-two week high of $60.90. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -14.64 and a beta of 1.82. The firm's fifty day moving average is $44.36 and its 200 day moving average is $46.41.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday, November 19th. Finally, TD Cowen reissued a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.